

Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder

Newbury Pharmaceuticals is pleased to announce the successful enlargement of the portfolio with the addition of Dalbavancin 500mg Powder for infusion.

This niche antibiotic has been developed based on the reference brand Xydalba (EU) and is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).

With the addition of Dalbavancin, we have secured a niche and difficult to produce pharmaceutical with limited competition. In addition, we are also strengthening our strategic partnership with one of our trusted partners." says Mr Lars Minor CEO of Newbury

Regulatory filling will take place in the near future and launch of this medicine is planned in Sweden where the total annual value of the market is estimated to be 3,5 MEUR according to DLMI Nordic Pharma Insights.

Dalbavancin Powder is replacing a previously signed product, Daptomycin, from the same partner. The commercial attractiveness is judged to be better for Dalbavancin and no additional in-licensing fees will be paid.

For more information, contact:

Lars Minor, CEO lars.minor@newburypharma.com Mobile: +46 72-377 3005

www.newburypharma.com

About Newbury Pharmaceuticals

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at ca@vhcorp.se or +46 (0) 40 200 250.

Press Release 18 June 2024 08:45:00 CEST



Attachments

Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder